Forge Therapeutics Receives License from University of California, San Diego

 

SAN DIEGO, Dec. 22, 2015  Forge Therapeutics, Inc., a biotechnology company developing innovative medicines using a breakthrough drug discovery platform targeting metalloproteins, announced today it has obtained an exclusive license from the University of California San Diego to patent rights related to novel metalloprotein inhibitors discovered in the laboratory of Forge Therapeutics scientific co-founder Professor Seth Cohen, Ph.D.

“We are pleased to obtain exclusive worldwide rights to this intellectual property, which adds to our expanding and dominant patent portfolio protecting the development and commercialization of metalloprotein inhibitors,” said Zachary A. Zimmerman, Ph.D., CEO of Forge Therapeutics.  “In addition to strengthening our patent portfolio, we continue to apply our expertise in bioinorganic chemistry to discover and develop novel inhibitors against validated targets, potentially overcoming previous chemistry limitations in the industry.”

Subscribe to get the latest news